-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3555 Outcomes of Hematopoietic Stem Cell Transplantation in Primary Plasma Cell Leukemia: A Systematic Review and Meta-Analysis

Program: Oral and Poster Abstracts
Session: 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality)
Sunday, December 8, 2024, 6:00 PM-8:00 PM

Qamar Iqbal, MD1*, Sohaib Irfan, MD2*, Ahmad Basharat3*, Prashil Dave, MBBS4, Ahmed Hebishy, MBBCh5, Muhammad Kashif Amin, MD6*, Muhammad Umair Mushtaq7 and Moazzam Shahzad, MD8

1Hospitalist, TidalHealth, Salisbury, MD
2Aga Khan University, Karachi, Pakistan
3Marshfield Clinic Health System, Marshfield, Wisconsin, Marshfield, WI
4SUNY Downstate Health Sciences University, Brooklyn, NY
5East Carolina University/Brody School of Medicine, Greenville, NC
6Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS
7Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS
8H Lee Moffitt Cancer Center and Research Institute, Tampa, FL

Background: Hematopoietic cell transplantation is a pivotal treatment modality for primary plasma cell leukemia (pPCL). Historically, pPCL has a poor prognosis and given its rarity, randomized controlled trials to explore treatment modalities are limited. In this systematic review and meta-analysis, we aimed to examine the outcomes of Allogeneic (Allo-SCT) and Autologous stem cells (Auto-SCT) transplantation in the adult pPCL population.

Methods: Following the Preferred Reporting Items for Systemic Reviews and Meta-analysis (PRISMA) guidelines, a comprehensive literature search was performed on PubMed, Cochrane Register of Controlled Trials, Embase, and Clinicaltrials.gov using MeSH terms and keywords for “Plasma cell leukemia” “Hematopoietic Stem Cell Transplantation” AND “therapeutics” from the date of inception till June 31, 2024. Our search produced 603 articles. After excluding irrelevant and review articles during primary and secondary screening, twelve original studies reporting outcomes of Allo-SCT and/or Auto-SCT in pPCL were included. The inter-study variance was calculated using the Der Simonian-Laird Estimator proportions and a 95% Confidence Interval (CI) was extracted to compute pooled analysis using the ‘meta’ package by Schwarzer et al. in the R programming language (version 4.3.0).

Results: A total of 1757 pPCL patients aged 18 years or older with auto-SCT or Allo-SCT were included in the analysis, and 49% of the participants were males (n=861/1757). The auto-SCT cohort comprised 1535 patients from 11 studies, with a median age of 57.35 (25-85) years, while the Allo-HCT group included 222 patients from six studies, with a median age of 49.5 (20-68) years. The median follow-up time was 4.03 (0.2-12.4) years in the auto-SCT and 3.35 years (0.25-7.6) in the Allo-SCT group. The median time to transplant was 0.53 (0.16-7.8) years and 0.55 (0.16-4.8) years in auto-HCT and Allo-HCT groups, respectively. The pooled 3 years overall survival (OS), progression-free survival/Event-free survival (PFS/EFS), and relapse rate (RR) in Auto-SCT were 51% (95% CI 0.4-0.61, I2=92%, p=<0.01), 36% (95% CI 0.24-0.52, I 2 =97%, p<0.01), and 68% (95% CI, 0.65-0.71, I2=0%, p=0.42), respectively. Among Allo-SCT recipients, the reported OS varied from 71% at 2.3 years (Landsburg et al.) to 31% at 4 years (Dhakal et al.), and EFS/PFS from 29% at 2.5 years (Royer et al.) to 19% at 4 years (Dhakal et al.). The pooled treatment-related mortality (TRM) was 12 % (95 % CI 0.05-0.25, I 2=35 %, p=0.22) at a median of 6 months. The pooled acute and chronic graft versus host disease (aGvHD and cGVHD) incidences were 27% (0.19-0.36, I2= 30%, p= 0.21) and 36% (0.27-0.45, I2= 24%, p= 0.26), respectively.

Conclusion: Our systematic review and meta-analysis show stem cell transplantation remains the backbone of primary plasma cell leukemia treatment. However, higher relapse rates warrant novel agents and clinical trials to improve transplant-related outcomes in this challenging subgroup.

Disclosures: Mushtaq: Iovance Biotherapeutics: Research Funding.

*signifies non-member of ASH